ResearcherGerman Cancer Research CenterActive in the last 2 years
Christian Teske
Matched on ORCID iD 0000-0002-6049-4765; OpenAlex author ID A5063111704. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 7
- Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial. Co-author DOI 10.3389/fonc.2025.1602933↗
- Molecular Spectroscopy for the Biochemical Composition Analysis of Patient-Derived Pancreatic Cancer Organoids. Co-author DOI 10.1002/cam4.70457↗
- Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectroscopy. Co-author DOI 10.1117/1.jbo.27.7.075001↗
- Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Co-author DOI 10.1007/s00423-021-02138-4↗
- Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2017.08.157↗
- Role of TFEB-driven autophagy regulation in pancreatic cancer treatment. Co-author DOI 10.3892/ijo.2016.3505↗
- Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Co-author DOI 10.1016/j.canlet.2014.12.037↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jürgen Weitz · 6 shared papers, 2016–2025 · strength 0.91
- Paper Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a si… DOI 10.3389/fonc.2025.1602933↗
- Paper Molecular Spectroscopy for the Biochemical Composition Analysis of Patient-Derived Pancreatic Cancer Organoids. DOI 10.1002/cam4.70457↗
- Paper Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectros… DOI 10.1117/1.jbo.27.7.075001↗
- Thilo Welsch · 5 shared papers, 2015–2022 · strength 0.50
- Paper Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectros… DOI 10.1117/1.jbo.27.7.075001↗
- Paper Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. DOI 10.1007/s00423-021-02138-4↗
- Paper Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer … DOI 10.1016/j.bbrc.2017.08.157↗
- Gerald R. Steiner · 2 shared papers, 2022–2024 · strength 0.40
- Marius Distler · 2 shared papers, 2021–2025 · strength 0.36
- Paper Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a si… DOI 10.3389/fonc.2025.1602933↗
- Paper Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. DOI 10.1007/s00423-021-02138-4↗
- Florian Schepp · 1 shared paper, 2025 · strength 0.24
- Sebastian Hempel · 1 shared paper, 2025 · strength 0.24
- Lena Seifert · 1 shared paper, 2025 · strength 0.24
- Florian Oehme · 1 shared paper, 2025 · strength 0.24
- Franziska Baenke · 1 shared paper, 2024 · strength 0.23
- Daniel E. Stange · 1 shared paper, 2024 · strength 0.23
- Christoph Kahlert · 1 shared paper, 2022 · strength 0.17
- Miriam Schenk · 2 shared papers, 2015–2016 · strength 0.13
- Tobias Keck · 1 shared paper, 2021 · strength 0.12
- Louisa Bolm · 1 shared paper, 2021 · strength 0.12
- Ulrich Friedrich Wellner · 1 shared paper, 2021 · strength 0.12
- Robert Grützmann · 1 shared paper, 2021 · strength 0.12
- Kathrin Klein · 1 shared paper, 2016 · strength 0.07
- Kristin Werner · 1 shared paper, 2016 · strength 0.07
- Nathalia A. Giese · 1 shared paper, 2015 · strength 0.06
- Berk Aykut · 1 shared paper, 2015 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.